2422045-23-4
Chemical Structure
D-T7-cys
- CAS No.: 2422045-23-4
- Formula:C44H65N15O10S
- Molecular Weight:996.15
InChIKey: SCSBHOHFPXUPCY-HLLHRLDNSA-N
SMILES: O=C(N[C@H](CCCNC(N)=N)C(N1[C@H](CCC1)C(N[C@H](CC2=CC=C(C=C2)O)C(N[C@H]([C@H](C)CC)C(N[C@H](C)C(N[C@H](CC3=CNC=N3)C(N[C@H](CS)C(O)=O)=O)=O)=O)=O)=O)=O)[C@@H](CC4=CNC=N4)N
Biological Activity: D-T7-cys is a D-T7 (HY-P11918) peptide with a C-terminal D-cysteine (HY-W018555). Nanoparticles modified with D-T7-cys serve as effective carriers for the delivery of compounds targeting the transferrin receptor (TfR). D-T7-cys reacts with DOX-SS-Pyr to form the DT7-SS-DOX conjugate. D-T7-cys is applicable to research related to glioma, autism spectrum disorder, glioblastoma, hepatocellular carcinoma, and lung cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-T7-cys | D-T7-cys is a D-T7 (HY-P11918) peptide with a C-terminal D-cysteine (HY-W018555). Nanoparticles modified with D-T7-cys serve as effective carriers for the delivery of compounds targeting the transferrin receptor (TfR). D-T7-cys reacts with DOX-SS-Pyr to form the DT7-SS-DOX conjugate. D-T7-cys is applicable to research related to glioma, autism spectrum disorder, glioblastoma, hepatocellular carcinoma, and lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yu M, et al. D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma. ACS applied materials & interfaces. 2019 Jan 09;11(1):176-186.
- [2]. He X, et al. Acid-Responsive Dual-Targeted Nanoparticles Encapsulated Aspirin Rescue the Immune Activation and Phenotype in Autism Spectrum Disorder. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2022 May;9(14):e2104286.
- [3]. Yu J, et al. New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity. Molecules (Basel, Switzerland). 2024 Apr 12;29(8):1758. [Content Brief]
